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Na channels are the source of excitatory currents for the nervous system and muscle.
They are the target for a class of drugs called local anesthetics (LA), which have been
used for local and regional anesthesia and for excitatory problems such as epilepsy and
cardiac arrhythmia. These drugs are prototypes for new analgesic drugs. The drug-binding
site has been localized to the inner pore of the channel, where drugs interact mainly with
a phenylalanine in domain IV S6. Drug afﬁnity is both voltage- and use-dependent. Voltage-
dependency is the result of changes in the conformation of the inner pore during channel
activation and opening, allowing high energy interaction of drugs with the phenylalanine.
LA drugs also reduce the gating current of Na channels, which represents the movement
of charged residues in the voltage sensors. Speciﬁcally, drug binding to phenylalanine locks
the domain III S4 in its outward (activated) position, and slows recovery of the domain IV
S4. Although strongly affecting gating, LA drugs almost certainly also block by steric occlu-
sion of the pore. Molecular deﬁnition of the binding and blocking interactions may help in
new drug development.
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INTRODUCTION
Local anesthetic (LA) drugs entered clinical use over a 100 years
ago for surgical pain control. They continue to be important for
local and regional anesthesia as well as for their cardiac antiar-
rhythmic actions. Their target is the voltage-gated Na channel,
and a great deal of research over the recent years has located the
binding site within the channel’s inner pore. As the ﬁrst class
of channel-active drugs to be studied extensively, they serve as
a model for other drug studies. In addition to cardiac arrhyth-
mias, the voltage-gated Na channel is an important player in many
pathophysiological processes, including pain and epilepsy. Many
drugs with dissimilar structures resemble LA drugs in their chan-
nel action and perhaps also in their binding sites. Consequently,
efforts to develop LA-like drugs with speciﬁc nerve blocking abili-
ties are widespread. Recently there has been considerable progress
in understanding the mechanism of voltage-dependent binding of
LA drugs. This article focuses on new insights into LA molecular
mechanism of action, which may assist in developing better and
more speciﬁc drugs.
CLINICAL ROLE OF LOCAL ANESTHETIC DRUGS TODAY
The primary use of LA drugs at this time is for local or regional
nerve block. Speciﬁc examples are dental procedures, eye surgery,
epidural anesthesia for lower abdominal or leg surgery, large
nerve block in the extremities for orthopedic surgery, and surgical
biopsy. High concentrations are achieved by local injection, so that
speciﬁcity is achieved at the site of injection while systemic effects
of the drugs are minimized. Desirable features are rapid onset of
nerve block, sufﬁcient block duration, and lack of local reaction.
LA drugs are also useful as antiarrhythmic agents for short-term
use for suppression of cardiac excitability during rapid arrhyth-
mias, and they can be lifesaving in acute ischemia. However,
their action can also establish the conditions for development
of arrhythmias, and their long-term use, especially in individuals
with ischemic heart disease, must be considered cautiously.
Several nervous system conditions can be treated with LA-type
drugs. Some of the commonly used anticonvulsant drugs blockNa
channels with LA-like characteristics. Because pain is transmitted
to the central nervous system via nerve cells that depend on spe-
ciﬁc isoforms of the Na channel for excitation and conduction,
agents that selectively target these Na channel isoforms that trans-
mit pain signals are eagerly sought, in order to avoid the use of
analgesic drugs that are addicting or have dangerous side effects.
STRUCTURE OF THE DRUG TARGET
The mammalian Na channel is an intrinsic membrane glycopro-
tein. It is a molecular complex of a ∼2000 amino acid α-subunit,
which contains the main channel functions and drug interaction
sites, and a variable number of smaller β-subunits, which mod-
ulate membrane expression and channel functional properties
(Catterall, 2000; Patino and Isom, 2010). The α-subunit contains
24 transmembrane segments organized into four homologous,
but not identical, domains (DI–DIV). The six transmembrane,
mostly α-helical segments in each domain (S1–S6) are further
divided into a voltage-sensing unit (S1–S4) and a pore-forming
unit (S5–S6), connected mainly through the S4–S5 cytoplasmic
linker. Much of the protein is not within the membrane, with the
glycosylated outside loops involved in toxin interactions, and the
larger cytoplasmic loops involved in hormonal and metabolic reg-
ulation. There are multiple isoforms of the Na channel α-subunit.
This discussion will focus on mammalian brain (NaV1.2) skele-
tal (NaV1.4), and cardiac (NaV1.5) Na channels, which are very
homologous in their intramembrane regions and which have been
the major isoforms used for structure–function studies.
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No direct detailed three-dimensional structural information
for the mammalian Na channel is available to date because of the
difﬁculty in developing crystals of these large amphipathic pro-
teins. The primary and secondary structures of Na channels are
similar to the better-studied K channel (e.g., Doyle et al., 1998;
Jiang et al., 2002; Long et al., 2005), and it is expected that ter-
tiary structure will be also. The crystal structure of a bacterial
voltage-gated Na channel (NaVAb) has been recently reported
(Payandeh et al., 2011). In contrast to the mammalian Na channel,
it is comprised of four identical subunits, rather than four con-
nected non-identical domains. Nevertheless, its structure will be
of great value in the interpretation of experimental studies. The
structure of K channels and the bacterial Na channel, combined
with studies of mammalian channel chimeras and point muta-
tions, have allowed the development of molecular models of the
mammalian Na channel α-subunit (Guy and Seetharamulu, 1986;
Lipkind and Fozzard, 2005; Bruhova et al., 2008).
The part of the channel that is best characterized by modeling
is the pore region,which has been useful in locating drug and toxin
binding sites. The pore is formed mainly by a bundle of the four
non-identical S6 α-helical segments, one from each domain. The
pore outer vestibule is lined by four infolded hairpin loops of the
S5–S6 extracellular regions (P loops) that form the outer vestibule
and selectivity ﬁlter of the channel, which is located about 40%
through the pore from the outside. The outer vestibule and selec-
tivity ﬁlter contain several charged amino acid residues, but the
inner pore is composed of neutral, mostly hydrophobic amino
acid residues.
The voltage-sensing S4 segments are similar to those of voltage-
gated K channels, as well as to those of the recently crystalized
bacterial Na channel (Payandeh et al., 2011). The S4 segments
contain several positively charged residues that are responsive to
changes in the transmembrane potential, and their function has
been explored by selective mutation (for review, see Bezanilla,
2000). Critical to the function of the Na channel is its ability to
open and close its pore in response to changes in the transmem-
brane potential, a process called voltage-dependent gating. The
channel is closed at the resting potential, and opens brieﬂy upon
depolarization. Based upon crystal structures of K channels (Doyle
et al., 1998; Jiang et al., 2002) and the NaVAb channel (Payandeh
et al., 2011), the activation gate of Na channels is located at the
cytoplasmic end of the pore, where all four S6 segments converge.
The current understanding on opening of the activation gate is
that a hinged motion of the S6 segments allows them to sepa-
rate at their cytoplasmic ends resulting in an open pore (Jiang
et al., 2002). Changes in the S6 conformation are linked to move-
ment of the positive charges in the S4 segments, i.e., the voltage
sensors, toward the extracellular surface of the membrane during
depolarization. Each individual S4 pulls on its S4–S5 cytoplasmic
segment, which is adjacent to the S5–S6 pore-wall at its cytoplas-
mic end, resulting in opening the channel pore (Long et al., 2005).
The pore then is occluded (inactivated) by the movement of the
intracellular segment formed by the linker between domains III–
IV, i.e., the inactivation particle, into the open pore (Patton et al.,
1992), and facilitated by the voltage-dependent movement of the
domain IV S4 segment (Chahine et al., 1994; Sheets et al., 1999).
Upon repolarization these processes appear to be reversed.
LOCAL ANESTHETIC DRUG-BINDING SITE(S)
The functional characteristics of LA action at concentrations of
clinical relevance are complex, but they can be divided into three
categories (Sheets et al., 2010). Firstly, when the channel is in the
closed conformation, i.e., at very hyperpolarized potentials, block
of Na current occurs only at high concentrations (mM range).
Secondly, when the channel is opened with batrachotoxin, rapid
ﬂicker block can occur by block at the selectivity ﬁlter. This ﬂicker
block, when evident, is low afﬁnity, i.e., in the millimolar range.
The third type is high-afﬁnity block, and it represents interaction
of LA’s with the pore conformation that occurs when the voltage
sensors are deployed outward and the channel is in its open state
and/or open-inactivated state. This occurs at positive potentials
and is simply called voltage-dependent block.
The long-standing explanation for high-afﬁnity LA block is
called the “modulated receptor hypothesis” (Hille, 2001). It pro-
poses that LA high-afﬁnity depends on structural modiﬁcation of
the binding site (the LA receptor) as a consequence of channel
opening and inactivation. Sorting out the types of block using
electrophysiology can be less than straight-forward because; (1)
channel conformation is voltage dependent, (2) there may be lim-
itations in access and egress to various channel conformations,
depending on chemical properties of the drug, and (3) drug on
and off rates can be shorter than, in the same order of magnitude
as, or longer than channel conformational lifetimes. In voltage
clamp assays, block of closed channels is usually tested by hold-
ing at very negative potentials, i.e., usually at least −120mV or
more negative with infrequent depolarization for a short dura-
tion. This is sometimes called “resting block,” but experimental
measures differ greatly, because the holding potential can fail to
be sufﬁciently negative to remove all voltage-dependent block.
Resting block (also called closed-state or lipophilic-block) can be
conﬁrmed as such when the amount of block is not decreased by
further hyperpolarization. Strict open-channel, ﬂicker block can
occur at potentials that also support high-afﬁnity block, but it
requires much higher drug concentrations; it has been assayed by
single channel recordings in channels where inactivation is pre-
vented with batrachotoxin (e.g., Zamponi et al., 1993). Flicker
block is not likely to be of clinical signiﬁcance.
Other electrophysiological assays, which are often of the most
physiological relevance, represent a mixture of several types of
block in combination with drug access/egress properties. For
example, for many LA drugs (and especially those considered to
be antiarrhythmic), repetitive test depolarizations showaccumula-
tion of block, a property called “use-dependence.”Use-dependent
increase in block can occur because drug off rates from the high-
afﬁnity site are sufﬁciently slow that dissociation is not complete
between test depolarizing steps either because of high drug-
binding afﬁnity (such as lidocaine compared to benzocaine;Hanck
et al., 2009) or because of limited egress (such as ﬂecainide; Liu
et al., 2003). In fact, protocols with rapid trains of depolarizations
are often used as a surrogate for assaying the high-afﬁnity state,
since it is non-conducting and therefore amenable to direct mea-
surement only by methods that do depend on measuring ionic
current, e.g., binding assays or gating current.
Early information about the location of the high-afﬁnity LA
binding site, summarized by Hille (2001), indicated that it was on
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theNa channelα-subunit and accessible from the cytoplasmic side.
Because homology modeling and chemical reactivity studies indi-
cated that the inner pore was most likely lined with residues of the
S6 segments, Catterall and associates systematically mutated these
residues and determined the effects on LA block at depolarized
potentials (Ragsdale et al., 1994; Yarov-Yarovoy et al., 2002). They
found only two residues that had a major effect on high-afﬁnity
block; Phe-1764 and Tyr-1771 in DIVS6. This is NaV1.2 (brain
isoform) numbering; for the skeletal muscle isoform (NaV1.4), it
is Phe-1579, and for the cardiac isoform (NaV1.5), it is Phe-1759
or Phe-1760 (depending on which clone is used). So far, no dif-
ferences in the binding interactions have been identiﬁed for these
isoforms. Consequently, to simplify further discussion of these
residues independent of the isoform studied, theywill be identiﬁed
as IVS6-Phe and IVS6-Tyr. Mutation of Ile-1760 also had effects
although it is probably not part of the binding site (see below).
Small effects of uncertain mechanism were noted for mutations of
Leu-1465,Asn-1466,and Ile-1469 inDIIIS6,and Ile-409 andpossi-
bleAsn-418 inDIS6. In contrast, the low afﬁnity, closed-state block
seen with test depolarizations from very hyperpolarized potentials
was not reduced by these mutations, and may have been slightly
increased. This demonstrated clearly that the low afﬁnity and the
high-afﬁnity sites are clearly different. Indeed, the high-afﬁnity
block can be abolished by removal of only IVS6-Phe (Hanck et al.,
2009).
Docking of LA drugs into homology models of the open, inner
pore of the Na channel (Figure 1) illustrate the structure of a pos-
sible high-afﬁnity binding site (Lipkind and Fozzard, 2005). The
typical LA drug has a tertiary amine hydrophilic domain and an
aromatic ring hydrophobic domain, separated by an intermediate
linker containing an amide or an ester group. Consistent with the
suggestion by Ragsdale et al. (1994), the Lipkind–Fozzard model
had the alkylamine group interact with IVS6-Phe and the aromatic
ring interact with IVS6-Tyr. The alkylamine group ﬁtted into a
space between IVS6-Phe and the leucine in IIIS6, which was cre-
ated by opening of the pore, with a van der Waals energy of about
−4 to −5 kcal/mol, and the aromatic ring interacted with IVS6-
Tyr with an energy of about −2 to −3 kcal/mol. Replacement of
IVS6-Phewith alanine in themodel reduced the interaction energy
about 3 kcal/mol, consistent with experimental evidence that this
substitution abolished measurable voltage-dependent LA block.
Ahern et al. (2008) systematically reduced theπ-electron charge of
IVS6-Phe by incorporation of unnatural amino acids at this posi-
tion, and they demonstrated that the LA interaction with pheny-
lalanine is due to an electrostatic force. Block by benzocaine,which
contains the hydrophobic aromatic ring, but not the partially
charged alkylamine end, was not inﬂuenced by their unnatural
amino acid substitutions. The aromatic end of LA drugs interacted
in the model with IVS6-Tyr with an energy of about−3 kcal/mol,
and the interaction was not an aromatic–aromatic one. Interac-
tion of the drug aromatic moiety with IVS6-Tyr was investigated
by Li et al. (1999) using tetracaine. They found that substitution
of IVS6-Tyr by hydrophobic residues producedminimal change in
use-dependent LA block, consistent with an aliphatic interaction
rather than an aromatic-aromatic one. In keeping with experi-
mental data the model did not show interaction with residues in
DIS6 or DIIS6.
FIGURE 1 | Molecular model of lidocaine in its binding site in the Na
channel inner pore. IVS6-Phe and IVS6-Tyr are shown as green space-ﬁlled
images, and IIIS6-Leu is shown as blue spaced-ﬁlled images. IIIP-Lys is part
of the DEKA selectivity ring and is shown as purple stick ﬁgures. Lidocaine
in CPK space-ﬁlled images interacts with IVS6-Phe and IVS6-Tyr, almost
ﬁlling the pore. The ﬁgure was prepared by Gregory Lipkind.
Because of their size, charged lidocaine-like molecules did not
ﬁt well into the inner pore of the Lipkind–Fozzard model of the
closed Na channel. In the closed pore model both IVS6-Phe and
IVS6-Tyr face the central pore lumen, but the cleft between IVS6-
Phe and the leucine in IIIS6 is too small to allow the alkylamine to
ﬁt. IVS6-Tyr is part of the densely packed S6 crossing in themodel.
In the bacterial NaVAb, the crossover is located lower (Payan-
deh et al., 2011), but experimental study of accessibility of MTS
reagents supports the mammalian model (Sunami and Fozzard,
unpublished data). According to themodel, charged LA drugsmay
not be able to enter the inner pore, or if they do (possibly through
pore-wall fenestrations, as noted in the NaVAb structure; Payan-
deh et al., 2011), they do not form strong interactions with the key
residues of IVS6-Phe and IVS6-Tyr. Therefore, LA drugs appear
to bind with high-afﬁnity to two residues in DIVS6 and possibly
with low afﬁnity to one or more in DIIIS6 in the inner pore when
the binding site is optimized by the conformational changes that
occur during channel voltage-dependent activation and opening.
IVS6-Phe is the most important residue for LA binding, and its
mutation abolishes voltage-dependent, i.e., use-dependent, block.
The site of LA binding for low afﬁnity closed-channel block is
not yet clearly resolved, and may be simply a combination of
hydrophobic interactions with the closed pore.
ROLE OF THE DRUG ACCESS PATH
The location of the LA binding site has depended upon the study
of point mutational data that assume that impairment of drug
block of Na current by point mutations involve parts of the drug-
binding site. However, there are two other possible explanations
for the effects of amino acid substitutions: (1) the mutation could
interfere with a molecular sequence of events downstream of
the binding step without being part of the binding site itself.
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All evidence at this point supports the direct role in binding by
IVS6-Phe and probably IVS6-Tyr, but roles of the others are less
certain. (2) Another possible action of mutations is to alter the
drug pathway to and from its binding site deep within the inner
pore. Although LA drugs access their high-afﬁnity binding site
only from the inside for most Na channel isoforms (Narahashi
and Frasier, 1971; Strichartz, 1973), two early experimental stud-
ies suggested that access to the inner pore site is possible from
the outside. Alpert et al. (1989) used a cardiac cell preparation
with independent perfusion of the outside and the inside and
found that QX314, a permanently charged quaternary amine that
is membrane impermeant, could block cardiac Na current from
the outside. At that time, it was not clear whether QX314 could
access the inner pore site directly or if there was another bind-
ing site. When Ragsdale et al. (1994) observed that replacement
of Ile-1760 by alanine in NaV1.2 reduced etidocaine block, they
determined that this was not the result of a loss of afﬁnity, but
of a more rapid off-rate. This mutation also generated channels
that were sensitive to extracellularly applied QX314. Subsequently,
Qu et al. (1995) showed that an isoform difference in the upper
part of DIVS6 between the nerve channel (NaV1.2) and the car-
diac channel (NaV1.5) was responsible for an external LA access
path in the cardiac isoform, and Sunami et al. (1997) found that
an isoform difference in the selectivity region also allowed extra-
cellular LA to block the cardiac channel. These external access
paths can affect lidocaine block, but only in the cardiac isoform
(Lee et al., 2001). Bruhova et al. (2008) have explored the possi-
ble molecular paths for external access in their model of the Na
channel.
MECHANISM OF LA BLOCK OF THE Na CHANNEL
Location of the LA binding site in the open-channel inner pore
suggests several possible mechanisms for high-afﬁnity LA block. A
key to approaching this question is recognition that high-afﬁnity
block is voltage dependent over the range that the Na channel acti-
vates to open the pore. These voltage-dependent conformational
changes appear to create the high-afﬁnity site composed mainly of
IVS6-Phe and IVS6-Tyr. Block could occur because the LA mol-
ecule binds in the inner pore and physically blocks conductance,
because drug-binding interferes with the gating machinery itself,
or both. Experimental evidence can be found to support both
possibilities.
Physical obstruction of the pore would be voltage dependent
because the channel’s conformational changes during activation
create the high-afﬁnity site. Molecular modeling is consistent with
this idea, with the bound drug located horizontally across the
pore (Hanck et al., 2009). LA drugs all produce complete block
at the single channel level, i.e., reduction in probability of open-
ing, associated with modest decrease in open times (Grant et al.,
1989). The selectivity ﬁlter is the narrowest segment of the pore,
and direct drug interaction with it can under some circumstances
produce fast ﬂicker block at very high concentrations (Zamponi
et al., 1993). However, electrostatic interaction of the positively
charged lidocainewith the negatively charged residues in the selec-
tivity ﬁlter suggests that the high-afﬁnity site is about 10 Å below
the selectivity ﬁlter (Sunami et al., 1997). For charged LA drugs,
the positive charge itself would be expected to interfere with per-
meation of Na, even if it does not occlude the pore completely
(McNulty et al., 2007).
The alternative idea for mechanism of block is that it inter-
feres with channel gating. The long-standing modulated receptor
hypothesis for blocking action of LA drugs predicted a stabiliza-
tion of the inactivated state of the Na channel (Hille, 1977). There
is ample evidence of interaction between LA drug binding and
gating. Voltage sensor movement, which is the mediator between
membrane voltage and conformational changes of gating, can be
measured directly by intramembranous charge movement, and
LA binding reduces this gating charge as much as 40% (Hanck
et al., 1994). The most dramatic effect of lidocaine on gating
currents is loss of the entire contribution of the DIIIS4 gating
charge, which normally contributes ∼30% to maximal charge
(Sheets and Hanck, 2003), along with loss of a part of the DIVS4
charge. It appears that lidocaine stabilizes the DIIIS4 voltage sen-
sor in its activated (depolarized) position, so that it is unable
to reset upon repolarization. Muroi and Chanda (2008) studied
the effects of lidocaine on ﬂuorescence indicators of individual
S6 segment movements in rat skeletal Na channels expressed in
Xenopus oocytes. They found a somewhat smaller reduction in
total gating charge (S1–S4) of ∼25%, with the greatest change in
ﬂuorescence-voltage curve in the DIIIS4. While the mechanism
is not understood in detail, it appears that LA drugs interfere
allosterically with return of DIIIS6 to its closed conﬁguration and
coupling to DIIIS4 via the S4–S5 linker prevents restoration of the
DIIIS4.
However, it is the DIVS4 that controls fast inactivation
(Chahine et al., 1994; Sheets et al., 1999). Measurement of the
movement of the DIVS4 gating charge in drug-bound channels
has shown more modest changes; a small (∼10%) reduction in
total current (about 1/3 of the normal contribution of DIVS4)
associated with a shift to the left of its voltage dependence (Sheets
and Hanck, 2003). The shift to the left at more hyperpolarized
potentials appears to result from the bound LA drug stabilizing the
DIVS4 in a partially depolarized position, so its movement is facil-
itated upon depolarization (Sheets et al., 2010). The gating charge
movements of DIS4 and DIIS4, which are presumably responsible
for the fast activation of the Na current, were unchanged.
Does outwardmovement of DIIIIS4 andDIVS4 simply increase
lidocaine afﬁnity for steric block in the pore, or does lidocaine
binding cripple the gating process resulting in altered kinetics and
a non-conducting channel? Studies on Na channels that have had
both their S4’s in DIII and IV pre-stabilized in outward positions
usingMTSEA-biotin show dramatically increased afﬁnity for lido-
caine block, with perhaps the DIVS4 being the more important
player, supporting the idea of an increase in steric block by lido-
caine (Sheets and Hanck, 2007). Importantly, the pre-stabilization
of both the DIIIS4 and DIVS4 did not, by themselves, prevent
the channel from opening and closing normally and conducting
current in the absence of LA drug. Consequently, the lidocaine-
induced effects on gating currents do not directly cause block of
channel conductance, but instead, they enhance lidocaine afﬁn-
ity. Arcisio-Miranda et al. (2010) mutated multiple residues in the
S4–S5 and terminal S6 regions of DIII and found several muta-
tions that dramatically reduced the stabilizing effect of lidocaine
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on the DIIIS4 gating charge, but in most cases these mutations
failed to prevent high-afﬁnity (use-dependent) lidocaine block.
This conﬁrms the important role of the molecular link between
DIIIS4–S5 and DIIIS6 in lidocaine effect on DIIIS4, and it also
conﬁrms that the DIIIS4 stabilization by lidocaine does not in
itself produce the block. Arcisio-Miranda and colleagues have not
reported comparable experiments on the DIVS4 movement.
High-afﬁnity block is most likely the result of occlusion of the
pore permeation path by the LA drugs (Hanck et al., 2009). This
process is voltage dependent because it depends on conforma-
tional changes during activation to create the high-afﬁnity site,
as predicted by the modulated receptor hypothesis. These confor-
mational changes also favor binding of the DIII–DIV inactivation
loop, and its binding may help stabilize the LA binding site in its
high-afﬁnity conformation.Adetailed understanding of how inac-
tivation is related to the kinetics of LA block remains unclear, and
there are conﬂicting reports on the effects of inactivation on lido-
caine block.Vedantham andCannon (1999) reported that the IFM
blocking segment within the intracellular linker between domain
III and IV, i.e., the inactivation particle, is not stabilized by lido-
caine, but it returns quite normally to its unbound position upon
repolarization in drug-bound Na channels. Chemical removal of
inactivation has been reported to reduce LA afﬁnity (Bennett et al.,
1995). However, a mutation that removes inactivation apparently
fails to reduce lidocaine afﬁnity (Wang et al., 2004). It also remains
possible that high-afﬁnity LAdrug-binding favors some ill-deﬁned
closed-state of the inner pore occurringnaturally during slow inac-
tivation (Ong et al., 2000) or a unique LA-induced closed-state.
Recovery from LA block after repolarization would then depend
on unbinding of the LA molecule accompanied by movements of
the DIIIS4 and DIVS4 sensors and the inactivation particle, with
resulting loss of the high-afﬁnity site. Regardless of the details,
which need careful experimental study, it is clear that the link
between drug binding in the pore and voltage sensor movements
provides a mechanism to control drug afﬁnity dynamically and,
thereby, provides for a range of therapeutic options. It would be
helpful if future experimentation determined how drug binding
to residues in the S6 segment of domain IV is coupled to the
movements of the voltage sensor in domain III, and sorted out the
relationship of drug afﬁnity to conformational changes induced
by movement of IVS4 and its associated inactivation processes.
Although useful isoform differences in LA drug action have been
difﬁcult to ﬁnd, many opportunities have not yet been explored.
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